Medication info

Linagliptin Metformin Duo Tablet 2.5/850mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Daewoo Pharmaceutical Co., Ltd.
Appearance
Bright orange, biconvex, oval film-coated tablet
Packaging
60 tablets (10 tablets/PTP packaging x 6)
Approval status
Expired

MFDS item code 201905852 · Approved 2019.08.19

This product's status changed to Expired on 2024.08.19. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. Dose increases should be gradual to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently treated with metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased up to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment In patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, this medicine may be used with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component. (See Precautions for Use, 1. Do not administer to the following patients).

Ingredients

Manufacturer
Daewoo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes

  • Difficulty in blood sugar control for patients with type 2 diabetes
  • insufficient blood sugar control
View approved original text

This medication is used in conjunction with diet and exercise to help control blood sugar levels in adult patients with type 2 diabetes. It can be administered to patients who have not previously received diabetes medication or who find it difficult to control blood sugar levels with monotherapy. Additionally, this medication is added when Metformin monotherapy is insufficient. It can also be used to replace the combination of Linagliptin and Metformin or when it is difficult to control blood sugar levels with maximum doses of Metformin and sulfonylureas or insulin. When used in combination with Empagliflozin, it also aids in improving blood sugar control. In summary, this medication is effective in improving blood sugar control in various mono or combination therapies.

How to take

Adult dose

The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. Dose increases should be gradual to reduce gastrointestinal adverse reactions associated with metformin use. 1. Patients not currently treated with metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased up to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to include linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment In patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other condition that may increase the risk of lactic acidosis, this medicine may be used with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component. (See Precautions for Use, 1. Do not administer to the following patients).

Precautions

This medication helps in controlling blood sugar levels. However, it should not be used in certain patients, for example, those who are allergic to the components of this medication, those with severe renal impairment, those in acute infection or shock states, those with poor liver function, and women who are pregnant or breastfeeding should not take this medication. Due to the Metformin component, this medication may cause lactic acidosis, a rare but serious side effect. Lactic acidosis is a condition caused by an excessive buildup of lactic acid in the body, which can manifest as symptoms such as difficulty breathing, abdominal pain, and lethargy. If such symptoms occur, consultation with a physician must be sought immediately, especially for patients with acute renal failure or heart disease. Additionally, there is a risk of hypoglycemia, so when taken with other blood sugar-lowering medications such as insulin or sulfonylureas, blood sugar should be monitored frequently, and medication doses adjusted according to the physician's instructions. Older adults or patients with renal impairment should undergo regular kidney function tests before and during treatment with this medication, and if kidney function falls below a certain threshold, this medication should be discontinued. This medication may cause unusual reactions such as acute pancreatitis, severe joint pain, and skin rashes, so if any of these symptoms arise, the physician should be notified immediately. During treatment, it is advisable to avoid alcohol consumption, and caution is required in dehydration or severe gastrointestinal disorders. If using iodinated contrast media for radiological exams, this medication should be discontinued for a certain period before and after the examination, and it should also be discontinued for a certain period before and after surgery. Women who are pregnant or planning to become pregnant should not use this medication and should consult a physician to find appropriate methods for blood sugar control. Finally, this medication should be stored in a safe place out of reach of children and should not be transferred to other containers; it should be stored in a moisture-free environment.

Side effects

  • Lactic acidosis
  • vitamin B12 reduction and deficiency
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
Show 139 more
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • angioedema
  • urticaria
  • pruritus
  • erythema
  • rash
  • pemphigus-like eruptions
  • severe joint pain with disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • constipation
  • stomatitis
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's type dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • renal transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • osteoarthritis
  • limb pain
  • dizziness
  • sensory loss
  • chest discomfort
  • asthenia
  • epistaxis
  • oropharyngeal pain
  • voice disorder
  • allergic rhinitis
  • exertional dyspnea
  • wet cough
  • rhinorrhea
  • lung mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • increased serum triglycerides
  • increased urine albumin/creatinine ratio
  • positive urine leukocytes
  • reduced hemoglobin
  • increased serum potassium
  • increased serum creatinine
  • increased serum creatine kinase
  • increased ALT
  • male pattern baldness
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • insomnia
  • depression
  • altered state
  • nocturia
  • dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and humidity and must be stored in a tightly sealed container. The storage temperature should be maintained between 1 and 30 degrees Celsius at room temperature. Doing so will help maintain the efficacy and safety of the medication for a long time.

Appearance and packaging

Appearance

Bright orange, biconvex, oval film-coated tablet

Package unit

60 tablets (10 tablets/PTP packaging x 6)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.